EFFECTS OF VARIOUS FACTORS ON STEADY-STATE PLASMA-CONCENTRATIONS OF TRAZODONE AND ITS ACTIVE METABOLITE M-CHLOROPHENYLPIPERAZINE

被引:50
作者
ISHIDA, M
OTANI, K
KANEKO, S
OHKUBO, T
OSANAI, T
YASUI, N
MIHARA, K
HIGUCHI, H
SUGAWARA, K
机构
[1] HIROSAKI UNIV HOSP,DEPT NEUROPSYCHIAT,HIROSAKI,AOMORI 036,JAPAN
[2] HIROSAKI UNIV HOSP,DEPT PHARM,HIROSAKI,AOMORI 036,JAPAN
[3] GOSHOGAWARA CITY HOSP,DEPT PHARM,GOSHOGAWARA,JAPAN
[4] AKITA UNIV HOSP,DEPT PSYCHIAT,AKITA,JAPAN
关键词
M-CHLOROPHENYLPIPERAZINE; PLASMA CONCENTRATION; SMOKING; STEADY STATE; TRAZODONE;
D O I
10.1097/00004850-199510030-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine (mCPP) were studied in 43 depressed patients (19 males, 24 females) receiving trazodone 150 mg at bedtime for 1-3 weeks, Sixteen cases were smokers, and 19 cases were also receiving various benzodiazepines. The means (and ranges) of plasma concentrations of trazodone and mCPP, and the mCPP/trazodone ratio were 619 (251-1059) ng/ml, 59 (32-139) ng/ml and 0.100 (0.044-0.219), respectively. Smokers had significantly (p < 0.05) lower plasma concentrations of trazodone and higher mCPP/trazodone ratios than non-smokers, Age, sex and co-administration of benzodiazepines did not affect any plasma concentrations or the mCPP/trazodone ratio, In 11 cases where the dose was increased to 300 mg, neither plasma concentration/dose ratios nor the mCPP/trazodone ratio changed significantly, The present study thus suggests that: (1) there is a large interindividual variation in the metabolism of trazodone; (2) smoking enhances the metabolism, but age, sex and co-administration of benzodiazepines do not affect it; (3) trazodone and mCPP have linear kinetics.
引用
收藏
页码:143 / 146
页数:4
相关论文
共 23 条
[1]   ALPRAZOLAM DOES NOT INHIBIT THE METABOLISM OF NORTRIPTYLINE IN DEPRESSED-PATIENTS OR INHIBIT THE METABOLISM OF DESIPRAMINE IN HUMAN-LIVER MICROSOMES [J].
BERTILSSON, L ;
ABERGWISTEDT, A ;
LIDEN, A ;
OTANI, K ;
SPINA, E .
THERAPEUTIC DRUG MONITORING, 1988, 10 (02) :231-233
[2]   PLASMA-CONCENTRATIONS OF TRAZODONE AND 1-(3-CHLOROPHENYL) PIPERAZINE IN MAN AFTER A SINGLE ORAL DOSE OF TRAZODONE [J].
CACCIA, S ;
FONG, MH ;
GARATTINI, S ;
ZANINI, MG .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1982, 34 (09) :605-606
[3]   GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN [J].
DAHL, ML ;
BERTILSSON, L .
PHARMACOGENETICS, 1993, 3 (02) :61-70
[4]   TOBACCO SMOKING AND DRUGS - A CLINICALLY IMPORTANT INTERACTION [J].
DARCY, PF .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (04) :302-307
[5]   TRAZODONE KINETICS - EFFECT OF AGE, GENDER, AND OBESITY [J].
GREENBLATT, DJ ;
FRIEDMAN, H ;
BURSTEIN, ES ;
SCAVONE, JM ;
BLYDEN, GT ;
OCHS, HR ;
MILLER, LG ;
HARMATZ, JS ;
SHADER, RI .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (02) :193-200
[6]  
JAUCH R, 1976, ARZNEIMITTEL-FORSCH, V26, P2084
[7]   EFFECTS OF M-CHLOROPHENYLPIPERAZINE IN NORMAL SUBJECTS - A DOSE-RESPONSE STUDY [J].
KAHN, RS ;
WETZLER, S ;
ASNIS, GM ;
KLING, MA ;
SUCKOW, RF ;
VANPRAAG, HM .
PSYCHOPHARMACOLOGY, 1990, 100 (03) :339-344
[8]   NEURO-ENDOCRINE EVIDENCE FOR SEROTONIN RECEPTOR HYPERSENSITIVITY IN PANIC DISORDER [J].
KAHN, RS ;
ASNIS, GM ;
WETZLER, S ;
VANPRAAG, HM .
PSYCHOPHARMACOLOGY, 1988, 96 (03) :360-364
[9]   META-CHLOROPHENYLPIPERAZINE AS A PROBE OF SEROTONIN FUNCTION [J].
KAHN, RS ;
WETZLER, S .
BIOLOGICAL PSYCHIATRY, 1991, 30 (11) :1139-1166
[10]   TRAZODONE, A CENTRAL SEROTONIN ANTAGONIST AND AGONIST [J].
MAJ, J ;
PALIDER, W ;
RAWLOW, A .
JOURNAL OF NEURAL TRANSMISSION, 1979, 44 (03) :237-248